Avenue Therapeutics is seeking to develop and commercialize therapies to treat central nervous system (CNS) disorders. There is a large unmet patient and market need in the CNS therapeutic space. Key to Avenue’s clinical development strategy is delivering near-term milestones that can build near-term value. Avenue’s portfolio includes two clinical stage programs, IV Tramadol for acute postoperative surgical pain and BAER-101 for epilepsy and acute anxiety. In particular, BAER-101 was licensed from AstraZeneca and can target the large market of patients with drug-resistant epilepsy. Through additional acquisitions in the CNS disease spaces, Avenue aims to further expand their pipeline.

Avenue Therapeutics

Founded: 2015
Location: New York, NY
Employee range: 1 - 10
Clinical stage: Clin2a
Therapy area: Spinal &amp; Bulbar Muscular Atrophy, Kennedy&#x27;s Disease
Drug types: MUS, NEU
Lead product: AJ201
Funding: $3.25M stock Jan 2023; $12M stock Oct 2022

Drug notes:

About:

Jobs: